Antibodies to Interferon beta in Patients with Multiple Sclerosis Receiving CinnoVex, Rebif, and Betaferon

Antibodies to Interferon beta in Patients with Multiple Sclerosis Receiving CinnoVex, Rebif, and Betaferon

Treatment with interferon beta (IFN-β) induces the production of binding antibodies (BAbs) and neutralizing antibodies (NAbs) in patients with multiple sclerosis (MS). NAbs against IFN-β are associated with a loss of IFN-β bioactivity and decreased clinical efficacy of the drug. The objective of this study was to evaluate the incidence and the prevalence of binding antibodies (BAbs) and neutral...

Cytokine patterns after therapy with Avonex®, Rebif®, Betaferon® and CinnoVex™ in relapsing-remitting multiple sclerosis in Iranian patients.

AIM Several lines of evidence exist which suggest that changes in the expression of circulating cytokines are linked to the development or reoccurrence of multiple sclerosis (MS). This study aimed to evaluate the serum levels of relevant cytokines after therapy with IFN-β formulations in MS patients. MATERIALS & METHODS In this study, blood samples were collected from 70 MS patients undergoin...

cytokine patterns after therapy with avonex®, rebif®, betaferon® and cinnovex® in relapsing–remitting multiple sclerosis in iranian patients

comparison of the effects of cinnovex, rebif and betaferon on a expanded disability status scale of patients with multiple sclerosis

patients and methods in this study, a total of 92 patients with relapsing-remitting multiple sclerosis (rrms) were randomly allocated into three equal groups; each treatment group received one of the foregoing drugs (cinnovexr, rebif and betaferon) for one year. at the beginning and end of the study, patients ‘ edss was measured and compared. results in this study, the relative frequency of fem...

Comparing the Safety and Efficacy of Ziferon and Betaferon in Patients With Remitting-Relapsing Multiple Sclerosis

Background: The present study aimed to compare the clinical efficacy and safety profile of Ziferon and Betaferon. Objectives: In total, 41 consecutive patients with relapsing forms of Multiple Sclerosis (MS) were selected from the MS outpatient clinic affiliated to Tehran University of Medical Sciences. The patients were randomly assigned into two groups. Methods: Each group either received Z...